Japan Results Round-Up: Astellas, Daiichi Sankyo, Chugai Solid, Shionogi Hits New Heights

Eisai Revenue Slips

Amid positive ongoing forex impact, Astellas, Shionogi and Daiichi Sankyo logged solid fiscal years and Chugai has good growth in its first quarter, although some of the majors are expecting a decline in sales as demand due to COVID-19 wanes. Even so, Shionogi logged record results on the back on government procurement of its pandemic antiviral.

Astellas, Daiichi Sankyo, Chugai all announced solid growths while Shionogi marked a record-high revenue.
Astellas, Daiichi Sankyo, Chugai had solid growth while Shionogi marked record high revenue • Source: Shutterstock

Major Japanese firms including Astellas, Shionogi and Daiichi Sankyo showed generally solid results with positive sales and mainstay growth in the fiscal year ended 31 March, as did Chugai in its first quarter, although the figures saw ongoing impact from forex on both sales (positive) and costs (negative). 

Astellas found hope from oncology drug Padcev (enfortumab vedotin) as its next key driver as the patent expiration for its...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Japan

More from Focus On Asia